evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

33 questions · 35 findings · 20 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 17.1%GRADE not reported 5 · 14.3%Very low 11 · 31.4%Low 9 · 25.7%Moderate 4 · 11.4%High 0 · 0%

Cells vs no cells

Cardiovascular mortality · Anyone diagnosed with AMI

Cells showed no clear difference in cardiovascular mortality ‐ long‐term compared with no cells (moderate certainty).

1 finding from 1 review

Glutamine‐supplemented nutrition vs non‐supplemented nutrition

Long‐term mortality (closest to six month) · critically ill patients or receiving major surgery

Glutamine‐supplemented nutrition showed no clear difference in long‐term mortality (closest to six month) compared with non‐supplemented nutrition (moderate certainty).

1 finding from 1 review

Levosimendan vs placebo

All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome

It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).

1 finding from 1 review

Levosimendan vs dobutamine

All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Long‐term all‐cause mortality (≥ 1 year after the intervention) · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes long‐term all‐cause mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Cardiovascular mortality · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes long‐term cardiovascular mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer

Non‐surgical showed no clear difference in long‐term mortality (binary outcome) All‐cause mortality for the… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).

2 findings from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term mortality (time‐to‐event outcome): radiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer

It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event outcome): radiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer

Non‐surgical showed no clear difference in long‐term mortality (time‐to‐event outcome): chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).

2 findings from 1 review